IDEHU   05542
INSTITUTO DE ESTUDIOS DE LA INMUNIDAD HUMORAL PROF. RICARDO A. MARGNI
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
OMP19S COADMINISTERED AS ADJUVANT INDUCES ANTIGEN CROSS PRESENTATION AND ELICITES CD8 T CELLS RESPONSES IN VIVO
Autor/es:
CORIA LM; IBAÑEZ AE; PASQUEVICH KARINA; GIAMBARTOLOMEI GUILLERMO; CASSATARO JULIANA
Lugar:
Viña del Mar, Chile
Reunión:
Congreso; 9th Latin American Congress of Immunology; 2009
Institución organizadora:
ALAI
Resumen:
<!--
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
@page Section1
{size:595.3pt 841.9pt;
margin:70.85pt 3.0cm 70.85pt 3.0cm;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
In previous studies we have shown that the protein moiety of Omp19 from
Brucella spp.(Omp19S) as adjuvant induces CD4+ T cell responses. In this study,
we evaluate the adjuvant capacity on CD8+ T cell responses using chicken
ovoalbumin (OVA) as an antigen model. C57BL/6 mice were adoptively transferred
with CFSE- labeled OT-1 T cells, which recognize a class I epitope of OVA. One
day later they were immunized s.c.
with OVA coadministered with: Omp19S, Omp19SPK (digested with Proteinase K),
LPS or PBS. Immunization with Omp19S as adjuvant induced greater OT-I cell
proliferation (CFSE dilution) than immunization with OVA without adjuvant or
OVA+Omp19SPK, and similar to the control LPS group. Moreover, the percentage of
OVA-specific IFN-g producing CD8+ T cells was significantly enhanced in the
OVA+Omp19S (0.73%) than in the OVA group (0.14%). Whereas immunization with
OVA+Omp19SPK failed to induce IFN-g producing CD8+ T cells, confirming that the
adjuvant capacity resides in the protein. In conclusion, we demonstrate that
Omp19S co administered adjuvant facilitates antigen cross-presentation and
induces IFN-g producing CD8+ T cells.